According to the World Health Organization, cancer diagnoses remain a leading cause of death. However, scientific and medical communities have improved clinical outcomes for many people, transforming ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of one ...
MRD detection via ctDNA poses challenges in managing breast cancer patients in complete remission, especially when imaging is negative. Enrollment in clinical trials is recommended for MRD-positive ...
Minimal residual disease (MRD)—minute populations of cancer cells undetectable by conventional imaging—remains the chief driver of relapse for patients. For years, detecting MRD has relied on invasive ...
OGT announced the launch of a new next-generation sequencing (NGS) panel for Measurable Residual Disease (MRD) - the SureSeq™ Myeloid MRD Plus NGS Panel. Designed using OGT’s 30 years of expertise in ...
Medical Device Network on MSN
Natera purchases Foresight Diagnostics
Cell-free DNA and precision medicine company Natera has acquired Foresight Diagnostics, a business known for its ...
We hypothesized that circulating tumor DNA (ctDNA) molecular residual disease (MRD) analysis without prior mutational knowledge could be performed after neoadjuvant chemotherapy to assess ...
Enables ultra-low variant detection across a range of key MRD targets in AML, including very large FLT3-ITDs Oxford, UK – 10 th November 2025. Today, OGT announced the launch of a new next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback